Zobrazeno 1 - 10
of 401
pro vyhledávání: '"PI3Kδ"'
Autor:
Xiao Yang, Huichen Bai, Xi Yuan, Xiaolong Yang, Ye Liu, Mingming Guo, Nan Hu, Beibei Jiang, Zeqin Lian, Zhilong Ma, Jingyuan Wang, Xuebing Sun, Taichang Zhang, Dan Su, Yue Wu, Jing Li, Fan Wang, Zhiwei Wang, Lai Wang, Xuesong Liu, Xiaomin Song
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101053- (2024)
PI3Kδ is a key signal transduction molecule in normal and malignant B cells, as well as in T-regulatory cells, making it a promising target for treatment of hematologic malignancies through both direct killing and anti-tumor immunity regulation. BGB
Externí odkaz:
https://doaj.org/article/6e9ecf70bc114685b74062abcfc58de0
Autor:
Vassilios Lougaris, Federico Le Piane, Caterina Cancrini, Francesca Conti, Alberto Tommasini, Raffaele Badolato, Antonino Trizzino, Marco Zecca, Antonio De Rosa, Federica Barzaghi, Claudio Pignata
Publikováno v:
Italian Journal of Pediatrics, Vol 50, Iss 1, Pp 1-11 (2024)
Abstract Activated phosphoinositide 3-kinase (PI3Kδ) Syndrome (APDS) is an inborn error of immunity (IEI) with a variable clinical presentation, characterized by infection susceptibility and immune dysregulation that may overlaps with other Primary
Externí odkaz:
https://doaj.org/article/c3a720bfdd824b72a325d875a42d7813
Autor:
Shuwen Jiang, Xiangkun Li, Weifang Xue, Sumei Xia, Jian Wang, Yang Sai, Guangxiu Dai, Weiguo Su
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively
Externí odkaz:
https://doaj.org/article/171a0dd993234a97b37b3479bb05b230
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract Parsaclisib, a potent and selective phosphatidylinositol 3 kinase δ inhibitor, has been investigated for the treatment of B‐cell malignancies and studied in patients with autoimmune diseases and myelofibrosis. The CITADEL‐101 study (NCT
Externí odkaz:
https://doaj.org/article/8c9671d0c4bb46a289d7e0fddc6c184e
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 11, Pp 1190-1195 (2023)
Abstract Background Many gaps remain in our understanding of the immune and molecular characteristics that underlie activated phosphoinositide 3‐kinase delta syndrome (APDS). Methods We performed RNA sequencing of peripheral blood leukocytes obtain
Externí odkaz:
https://doaj.org/article/a6bdb11f1003441db6c5078b889cda27
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 19, Iss 1, Pp 1-6 (2023)
Abstract Background Activated phosphoinositide3-kinase (PI3K) δ syndrome 1 (APDS1) is a novel inborn errors of immunity (IEIs) caused by heterozygous gain of function mutations in PI3Kδ catalytic p110δ (PIK3CD). APDS1 has a spectrum of clinical ma
Externí odkaz:
https://doaj.org/article/2828b32600b64b03b3b09fcfc67837c8
Autor:
Haote Han, Yanhui Yang, Yunjuan Jiao, Hui Qi, Zhuo Han, Luping Wang, Lijun Dong, Jingkui Tian, Bart Vanhaesebroeck, Xiaopeng Li, Junwen Liu, Gaoen Ma, Hetian Lei
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 738-748 (2023)
Gene editing with a CRISPR/Cas system is a novel potential strategy for treating human diseases. Pharmacological inhibition of phosphoinositide 3-kinase (PI3K) δ suppresses retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Here we
Externí odkaz:
https://doaj.org/article/a65629075e5e4ec989f356e8fd057ee8
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
IntroductionPI3K/AKT signaling pathway is upregulated in a broad spectrum of cancers. Among the class I PI3Ks (PI3Kδ/β/δ isoforms), PI3Kδ has been implicated in hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional
Externí odkaz:
https://doaj.org/article/1eae200900df4889b34fd432d1944e28
Autor:
Yingjue Li, Yiwen Li, Yu Yang, Yuwei Deng, Xiangdong Ni, Bochen Zhao, Zhaoqi Yan, Wen He, Yixin Li, Shuhui Li, Linbo Liu, Dan Lu
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18498- (2023)
Purpose: Endocrine resistance hormone receptor-positive (HR+) advanced breast cancer (ABC) is generally insensitive to immunecheckpoint inhibitors (ICIs). This study sought to determine whether PI3Kδ inhibitor could enhance the sensitivity of endocr
Externí odkaz:
https://doaj.org/article/b1ed9577c185450f955ac95c6e7c9986
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.